新型抗血小板靶标磷酸肌醇3-激酶β的研究进展
发布时间：2019-07-28 14:14
【摘要】：正当血管壁受损时,人体会启动止血途径来保护损伤的血管,但是抗凝血因子超出了正常调控范围,参与凝血的物质就会积聚于血管壁,导致病理性血栓形成。抗血小板药是治疗血栓的一类重要的药物,其主要以血小板聚集过程中的某些关键物质或信号途径作为治疗靶标,下调血小板整合素αⅡbβ3(GPⅡbⅢa)的黏附功能,达到治疗血栓的效果[1]。目前,抗血小板药物在治疗过程中,很可能抑制正常的止血途径而引发出血性
[Abstract]:When the vascular wall is damaged, the human body will initiate hemostatic pathway to protect the damaged blood vessels, but anticoagulant factors are beyond the normal range of regulation, and the substances involved in coagulation will accumulate in the vascular wall, leading to pathological thrombosis. Antiplatelet drugs are a kind of important drugs in the treatment of thrombus. Some key substances or signal pathways in the process of platelet aggregation are used as therapeutic targets to down-regulate the adhesion function of platelet integrin 伪 鈪，
本文编号：2520119
[Abstract]:When the vascular wall is damaged, the human body will initiate hemostatic pathway to protect the damaged blood vessels, but anticoagulant factors are beyond the normal range of regulation, and the substances involved in coagulation will accumulate in the vascular wall, leading to pathological thrombosis. Antiplatelet drugs are a kind of important drugs in the treatment of thrombus. Some key substances or signal pathways in the process of platelet aggregation are used as therapeutic targets to down-regulate the adhesion function of platelet integrin 伪 鈪，
本文编号：2520119
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2520119.html
最近更新
教材专著
